Within the pilot adoption running from June – September, these 18 journals will request but not require CRediT roles at submission from all contributors named on a manuscript. They will also optionally disclose ‘degrees of contribution’ for each role ‘claimed’ per contributor. Degrees demystify the ‘lead, equal, or supporting’ amounts of CRediT to be associated with contributions.
Within the framework of the pilot, CRediT information can also be updated post-acceptance within participating journals through ACS’s authorship/CRediT change process, prior to web publication.
Following the pilot, stakeholder feedback will be used to determine next steps toward potential wider roll out across the broader ACS portfolio.
With the addition of these 14 contributor roles, research contributors—who may play multiple roles in a single published work—can now have all facets of their work recognized. ORCID members can now add this data, enabling the information to be filtered to other systems that read ORCID data via the API or the public data file, thus creating greater transparency and recognition.
CRediT roles will be visible in the UI in the same way existing roles are, based on the user’s visibility preferences. As part of our ongoing work, we are continuing to look at ways we can allow users to include co-author and contributor data when adding research outputs to their ORCID record manually.
The ORCID API 3.0 now supports our existing list of contributor roles and CRediT roles, meaning that members can start using CRediT without having to upgrade to a newer API version. However, you will need to update your existing integration to begin leveraging CRediT.
Publishers can use Rescognito to manage CRediT outside of traditional publishing workflow
Rescognito allows researchers to claim CRediT using the DOI for their manuscript (just add the DOI to the end of the Rescognito URL. e.g.,https://rescognito.com/10.5281/zenodo.3899865… ). Following ORCID’s announcement of the addition of CRediT to records, Rescognito will implement functionality to push theseCRediT recognitions toORCID with the user’s permission. This is an option in addition to existing integrations with several Manuscript Submission and Peer Review systems, allowing for the management of CRediT upstream in publishing workflow. Stay tuned for more details as they develop!
AACR’s implementation is unique, in that they require the corresponding author to indicate each author’s contributions at first revision and each revision thereafter, and the system communicates these selections to each co-author in an individualized email alerting them to the completed submission. Each co-author is encouraged to contact the corresponding author regarding any requested changes to their declared contribution. This is possible through support from their submission and peer review system, eJournalPress.
“Before implementing CRediT, we solicited contributions from each co-author using electronic forms,” commented Daniel Evanko, Director of Journal Operations and Systems at AACR, “and we found that corresponding authors were sometimes surprised when they saw the article proof and the contributions claimed by a co-author. This could cause delays as we worked with authors to sort out contributions. The new workflow streamlines the process and increases transparency for all contributors, and accuracy for the scholarly record. While the implementation was very recent, we are generally very pleased with the adoption and implementation.”
“One of the most exciting things about the CRediT community is observing the diversity of approaches to implementation and integration, including workflow,” commented Alison McGonagle-O’Connell, NISO CRediT Working Group co-chair. “I’m looking forward to a future case study or author survey assessing preferences from this group who may have been exposed to both role solicitation workflows. I’m also thrilled AACR has joined the growing community of adopters!”
The integration is live for Blood Cancer Discovery, Cancer Discovery, Epidemiology, Biomarkers & Prevention, Cancer Immunology Research, Cancer Prevention Research, Cancer Research, Clinical Cancer Research, Molecular Cancer Research, and Molecular Cancer Therapeutics.